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S U M M A R Y
Objective: The aim of this study was to compare the Acute Physiology and Chronic Health Evaluation II
(APACHE II) score and the Clinical Pulmonary Infection Score (CPIS) for the prediction of 30-day mortality
in patients with ventilator-associated pneumonia (VAP).
Methods: A single-center, prospective cohort study design was employed between January 1, 2010 and
January 1, 2014. APACHE II and CPIS scores were determined on the day of VAP diagnosis. Discrimination
was tested using receiver-operating characteristic (ROC) curves and the areas under the curve (AUC).
Calibration was tested using the Hosmer–Lemeshow statistic.
Results: Of 135 patients with VAP, 39 died; the 30-day mortality was 28.9%. APACHE II and CPIS scores
were signiﬁcantly higher in non-survivors compared to survivors (23.1  4.8 vs. 16.7  4.6, p < 0.001;
6.8  1.3 vs. 6.2  1.3, p = 0.016). APACHE II had excellent discrimination for predicting 30-day mortality in
patients with VAP, with AUC 0.808 (95% conﬁdence interval (CI) 0.704–0.912, p < 0.001). However, the CPIS
score did not have discrimination power for predicting mortality, with AUC 0.612 (95% CI 0.485–0.739,
p = 0.083). The Hosmer–Lemeshow statistic showed good goodness-of-ﬁt for observed 30-day mortality and
APACHE II expected mortality (Chi-square = 1.099, p = 0.785). However, CPIS expected 30-day mortality did
not ﬁt the observed mortality (Chi-square = 6.72, p = 0.004).
Conclusions: These data suggest that APACHE II is useful for predicting 30-day mortality in patients with
VAP, but that the CPIS does not have good discrimination and calibration for predicting mortality.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Ventilator-associated pneumonia (VAP) is the most common
nosocomial infection in patients receiving mechanical ventilation.
The mortality rate of VAP patients ranges from 14% to as high as
70%.1–3 Studies have conﬁrmed that factors associated with
mortality are malignancy, inappropriate initial treatment, bacter-
emia, acute respiratory distress syndrome/acute lung injury, shock,
sepsis, disease severity, and the sepsis-related organ failure
score.1–4 Nevertheless, the accurate prediction of VAP mortality
based on these risk factors remains difﬁcult.* Corresponding author. Tel.: +86 513 85051868.
E-mail address: pphss@126.com (S.-S. Ni).
http://dx.doi.org/10.1016/j.ijid.2014.11.005
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).The Acute Physiology and Chronic Health Evaluation (APACHE)
II is a severity-of-disease classiﬁcation system. It was designed to
measure the severity of disease for adult patients admitted to the
intensive care unit (ICU).5 It has been conﬁrmed that APACHE II is a
very useful instrument for the prediction of ICU mortality by the
clinician.6 The Clinical Pulmonary Infection Score (CPIS) was
developed as a surrogate tool to facilitate the clinical diagnosis of
VAP.7 Studies have also found the CPIS to be an early clinical
predictor of the outcome of VAP.8,9 However, it is still not known
which of these is the better tool for predicting mortality in patients
with VAP.
The objective of this study was to evaluate and compare the
predictive value of the APACHE II score and CPIS for 30-day
mortality in patients with VAP.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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2.1. Study setting and design
This study was conducted at a university-afﬁliated hospital
serving a population of 7.74 million.
A single-center, prospective cohort study design was employed
between January 1, 2010 and January 1, 2014. The study was
approved by the Medicine Human Studies Committee of the
hospital, and the need for informed consent was waived.
Consecutive patients who stayed longer than 3 days in the
respiratory intensive care unit (RICU) and who developed VAP
were enrolled in the study. Patients younger than 18 years of age
and those with another source of infection or a malignancy were
excluded from the study.
2.2. Deﬁnition of VAP
VAP was deﬁned based on a modiﬁcation of the criteria
established by the American College of Chest Physicians.10 The
criteria require the occurrence of new and persistent radiographic
inﬁltrates in conjunction with two of the following: (1) a
temperature >38.5 8C or < 36.5 8C; (2) a white blood cell count
>12  109/l or <4  10>9/l; and/or (3) purulent tracheobronchial
secretions. Positive culture results from a protected specimen
brush (103 CFU/ml), plugged telescopic catheter specimen (103
CFU/ml), bronchoalveolar lavage ﬂuid specimen (104 CFU/ml), or
quantitative endotracheal aspirate (105 CFU/ml) were also
considered positive for the diagnosis of VAP.
2.3. Data collection
The APACHE II and the CPIS scores were determined on the day
of VAP diagnosis. Demographic data, admission diagnosis of the
patients, duration of mechanical ventilation, length of RICU and
hospital stay, comorbidities, pathogens responsible for VAP, and
30-day mortality were also recorded.
2.4. Statistical analysis
First, the primary data analysis compared 30-day non-survivors
with survivors. Continuous variables were compared using the
Student’s t-test for normally distributed variables. The Chi-square or
Fisher’s exact test was used to compare categorical variables.
Second, the discrimination of non-survivors and survivors was
tested using receiver-operating characteristic (ROC) curves and by
evaluating the areas under the curve (AUC). APACHE II and CPIS were
categorized into classes by selecting the best cut-offs. Third,
calibration for comparing observed and predicted mortality was
tested using the Hosmer–Lemeshow test. Logistic regressionPatients  receiving  mechanical  ventilatio 
Patients d evelope d VAP (n=151)  
P
Patients enr olled (n=1 35) 
Patients d ied in 30 days (n=39,  28.9%) 
Figure 1. Flow diagram of patieanalysis was applied to estimate the predictive 30-day mortality
of APACHE II and the CPIS. A two-tailed p-value of <0.05 was
considered statistically signiﬁcant. All analyses were performed
using IBM SPSS Statistics version 19.0 (IBM Corp., Armonk, NY, USA).
3. Results
3.1. Patient characteristics
During the study period, 761 patients were admitted to the
RICU and received mechanical ventilation. A total of 151 patients
(19.8%) were diagnosed with VAP. Sixteen patients were excluded,
11 due to another source of infection and ﬁve due to malignancy,
leaving 135 patients in the study cohort. Among these patients,
39 died within the 30 days after VAP diagnosis, giving a 30-day
mortality of 28.9%. A ﬂow diagram of the patients included in the
study is given in Figure 1. The baseline characteristics of patients
grouped by their survival status are provided in Table 1. APACHE II
scores at the time of VAP diagnosis were signiﬁcantly higher in
non-survivors compared with survivors (23.1  4.8 vs. 16.7  4.6; p
< 0.001). The CPIS were also signiﬁcantly higher in non-survivors at
the time of VAP diagnosis (6.8  1.3 vs. 6.2  1.3; p = 0.016).
3.2. Discrimination for 30-day mortality
The AUC for APACHE II predicting 30-day mortality in patients
with VAP was 0.808 (95% conﬁdence interval (CI) 0.704–0.912, p <
0.001); the AUC for CPIS was 0.612 (95% CI 0.485–0.739,
p = 0.083). ROC curves for the two scoring systems for predicting
30-day mortality are shown in Figure 2. Table 2 shows the
sensitivity and speciﬁcity values for the cut-off points of the two
scoring systems. APACHE II >25 on the day of VAP diagnosis had
high sensitivity (84.6%) and speciﬁcity (78.1%) in predicting
mortality, but CPIS >7 had moderate sensitivity (74.4%) and low
speciﬁcity (49.0%).
3.3. Calibration for 30-day mortality
Table 3 shows the observed mortality and the APACHE II score
expected 30-day mortality for patients with VAP. Table 4 shows
the observed mortality and CPIS expected mortality. The APACHE II
expected 30-day mortality was 29.9% and the CPIS expected
mortality was 35.9%. These are both higher than the observed
actual 30-day mortality of 28.9%. The Hosmer–Lemeshow statistic
showed good goodness-of-ﬁt for observed 30-day mortality and
the APACHE II expected mortality (Chi-square = 1.099, p = 0.785).
However, the CPIS expected 30-day mortality did not ﬁt the
observed mortality (Chi-square = 6.72, p = 0.004). Calibration
curves are shown in Figure 3.n in  RICU  wer e in clud ed (n =761) 
Patients d id not deve lop VAP (n=61 0) 
atients exc luded (n =16) 
with another source  of infecti on (n=11)  
wit h mali gnancy  (n=5) 
Patients  sur vive d in  30 days  (n=9 6, 71.1%)  
nts included in the study.
Table 1
Baseline patient characteristics
Characteristics 30-day
non-survivors
(n = 39)
30-day
survivors
(n = 96)
p-Value
Age, years, mean  SD 64.5  12.7 62.4  12.3 0.375
Gender, male/female 21/18 59/37 0.415
Admission diagnosis,
COPD/non-COPDa
36/3 82/14 0.274
Comorbidities, n (%)
Coronary artery
disease
12 (30.8%) 21 (21.9%) 0.275
End-stage renal
disease
2 (5.1%) 7 (7.3%) 0.648
Hepatic disease 2 (5.1%) 6 (6.3%) 0.802
Diabetes 3 (7.7%) 8 (8.3%) 0.902
Multidrug resistance, n (%) 31 (79.5%) 51 (53.1%) 0.004b
APACHE II, mean  SD 23.1  4.8 16.7  4.6 <0.001b
CPIS, mean  SD 6.8  1.3 6.2  1.3 0.016b
SD, standard deviation; COPD, chronic obstructive pulmonary disease; APACHE,
Acute Physiology and Chronic Health Evaluation; CPIS, Clinical Pulmonary Infection
Score.
a Non-COPD included community-acquired pneumonia, asthma, pulmonary
embolism, and others.
b p < 0.05.
Figure 2. ROC curves for predicting 30-day mortality in patients with VAP
(discrimination).
Table 3
Observed mortality and APACHE II score expected 30-day mortality in patients with
VAP
APACHE II
category
Total 30-day
non-survivors
30-day
survivors
Observed
mortality
Expected
mortality
10 5 0 5 0.0% 6.4%
11–15 22 2 20 9.1% 10.5%
16–20 46 7 39 15.2% 18.1%
21–25 32 10 22 31.3% 35.6%
26–30 19 10 9 52.6% 54.1%
>30 11 10 1 90.9% 70.1%
Total 135 39 96 28.9% 29.9%
APACHE, Acute Physiology and Chronic Health Evaluation; VAP, ventilator-
associated pneumonia.
Table 4
Observed mortality and CPIS expected 30-day mortality in patients with VAP
CPIS
category
Total 30-day
non-survivors
30-day
survivors
Observed
mortality
Expected
mortality
4 0 0 0 0.0% 2.6%
5–6 32 4 28 12.5% 8.3%
7–8 33 11 22 33.3% 18.1%
9–10 48 14 34 29.2% 45.6%
10–12 22 10 12 45.4% 82.1%
Total 135 39 96 28.9% 35.9%
CPIS, Clinical Pulmonary Infection Score; VAP, ventilator-associated pneumonia.
Table 2
Four-fold table for predicting 30-day mortality with best cut-offs of the two scoring
systems
APACHE II (>25) CPIS (>7)
Observed
death
Observed
survival
Observed
death
Observed
survival
Expected death 33 21 29 49
Expected survival 6 75 10 47
Sensitivity, % 84.6 74.4
Speciﬁcity, % 78.1 49.0
APACHE, Acute Physiology and Chronic Health Evaluation; CPIS, Clinical Pulmonary
Infection Score.
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We used discriminatory and calibrator power to compare the
APACHE II and CPIS scores in predicting 30-day mortality in
patients with VAP. Discrimination is the ability of the model to
correctly separate the subjects into different groups. An AUC value
of 0.5 indicates that the test has no discriminatory ability, whereas
an AUC value of 1.0 indicates perfect diagnostic capability.11 AUCs
above 0.97 have been classiﬁed as excellent, between 0.93 and
0.96 as very good, between 0.75 and 0.92 as good, and less than
0.75 as obviously deﬁcient in discriminatory accuracy.12 Our study
showed the AUC for APACHE II in predicting mortality to be
0.808 and the AUC for the CPIS to be 0.612. Our study also showed
that an APACHE II score >25 had high sensitivity (84.6%) and
speciﬁcity (78.1%) in predicting mortality. Calibration is the degree
of correspondence between the estimated probability producedby the model and the actual observed probability. Although the
APACHE II expected 30-day mortality of 29.9% was higher than
the observed mortality of 28.9%, the Hosmer–Lemeshow statistic
showed the APACHE II expected mortality to ﬁt the observed
mortality (Chi-square = 1.099, p = 0.785). A previous study has
compared APACHE II, Sequential Organ Failure Assessment (SOFA),
and CPIS scores in predicting the prognosis of patients with VAP;
the researchers also found discrimination to be excellent for the
APACHE II (AUC 0.81; p = 0.001) and deﬁcient for the CPIS (AUC
0.63; p = 0.069).13 Our results are in agreement with those of this
previous study.
APACHE II, but not CPIS, showed good discrimination and
calibration for predicting 30-day mortality in patients with VAP.
We believe that the main reason for this is that the APACHE II was
designed as a severity-of-disease classiﬁcation and the CPIS was
developed for the clinical diagnosis of VAP. APACHE II includes
an acute physiology score, age points, and chronic health points.5
The CPIS includes six parameters: temperature, white blood
cell count, tracheal secretions, PaO2/FiO2, chest radiography,
and microbiology.7 These six parameters are directly related to
infection. In our study, 39 patients (28.9%) died within 30 days
after the diagnosis of VAP. Most of them died of multiple organ
failure. Hence, 30-day mortality in patients with VAP must not be
predicted by the CPIS. The CPIS may be a useful tool for predicting
the attributable mortality of VAP. This could be conﬁrmed in
future studies.
Figure 3. Calibration curves for predicting 30-day mortality in patients with VAP. The reference line represents perfect calibration. (A) APACHE II: the Hosmer–Lemeshow
statistic showed good goodness-of-ﬁt for observed 30-day mortality and the APACHE II expected mortality (Chi-square = 1.099, p = 0.785). (B) CPIS: the Hosmer–Lemeshow
statistic showed the CPIS expected 30-day mortality did not ﬁt the observed mortality (Chi-square = 6.72, p = 0.004).
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signiﬁcantly higher rate of multidrug-resistant organisms than
survivors (79.5% vs. 53.5%, p < 0.05). This suggests that multidrug
resistance may be a risk factor for 30-day mortality. We calculated
multidrug resistance for predicting 30-day survival and found a
sensitivity of 79.5% and speciﬁcity of 46.9%, with a Youden index
of 0.264. Thirty-day mortality is affected by multiple factors.
Multidrug-resistant organisms cannot explain the higher mortality
alone. Multidrug-resistant organisms are not included in APACHE
II. It is possible that the prediction power would be increased by
combining APACHE II and multidrug resistance. This will be
investigated in our next study.
An important limitation of this study was that we only
compared APACHE II and CPIS scores, and found APACHE II to
be useful in predicting VAP mortality. However APACHE II is
inconvenient for use by practicing physicians as it requires the
computation of multiple variables. Several simple scores have been
developed to predict VAP mortality, such as the IBMP-10 score
(Immunodeﬁciency, Blood pressure, Multilobar inﬁltrates, Platelet
count, and 10-day hospitalization) and PIRO score (Predisposition,
Infection, Response, and Organ failure).14,15 We did not compare
the APACHE II with these new scores in this prospective cohort.
These can be veriﬁed in other studies.
In conclusion, our results suggest that the APACHE II score
determined at the time of VAP diagnosis has good discriminatory
and calibrator power to predict mortality in patients with VAP.
However, the CPIS cannot be used as a tool to predict VAP mortality
because of low discriminatory and calibrator power.
Conﬂict of interest/funding: None.
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